Clinical Trial Update: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design [Phase 2]

View source ↗

Summary

This Phase 2 trial compares radiotherapy with cisplatin versus a docetaxel-cetuximab regimen in head and neck squamous cell carcinoma, focusing on ERCC1 biomark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• ERBITUX (cetuximab)
• Taxotere (docetaxel)

Snippet

Sponsor: Christopher Wilke | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING